KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Accumulated Expenses (2023 - 2025)

Aurinia Pharmaceuticals' Accumulated Expenses history spans 3 years, with the latest figure at $66.6 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 2.54% year-over-year to $66.6 million; the TTM value through Dec 2025 reached $66.6 million, up 2.54%, while the annual FY2025 figure was $66.6 million, 2.54% up from the prior year.
  • Accumulated Expenses reached $66.6 million in Q4 2025 per AUPH's latest filing, up from $49.5 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $66.6 million in Q4 2025 to a low of $42.4 million in Q1 2025.
  • Average Accumulated Expenses over 3 years is $53.9 million, with a median of $49.9 million recorded in 2023.
  • Peak YoY movement for Accumulated Expenses: grew 29.78% in 2024, then rose 2.54% in 2025.
  • A 3-year view of Accumulated Expenses shows it stood at $50.1 million in 2023, then grew by 29.78% to $65.0 million in 2024, then rose by 2.54% to $66.6 million in 2025.
  • Per Business Quant, the three most recent readings for AUPH's Accumulated Expenses are $66.6 million (Q4 2025), $49.5 million (Q3 2025), and $49.7 million (Q2 2025).